Introduction 33 "I want to order the AIDS test on one of my patients". So began a phone call I received in late 34
1985 from an oncologist. I explained that the HTLV III (the term HIV had not been adopted at 35 that time) antibody assay that had just been developed was not a test for AIDS, but was actually 36 a test designed to prevent virus transmission via blood or blood products. The assay had not 37 been FDA approved as a diagnostic test for AIDS (1) 
First Generation HIV antibody tests 46
Following the 1983 isolation and description of the virus associated with AIDS (3,4), diagnostic tests 47
were developed using separate Human T cell Lymphotropic Virus (HTLV III) (Abbot and 48 Electronucleonics) and Lymphadenopathy virus (LAV) (Genetic Systems) isolates. These ELISA and 49 chemiluminescent methods used proteins isolated from virus infected tissue cultures as antigenic 50 targets. The assays detected IgG antibody to HIV-1 only. The tests were empirically sensitive, but had 51 an antibody negative window of up to 12 weeks or more post infection (5). The high sensitivity, while 52 useful for protecting the blood supply, led to false positive results, especially when low risk individuals 53 were tested. False positive results were associated with infections, autoimmune disease, pregnancy and 54 unspecified conditions. Similar to syphilis testing, a second level of testing was added to improve 55 specificity. Two procedures were FDA cleared as confirmatory tests for HIV-1 antibody only; the 56 western blot (6) and an HTLV III immunofluorescent assay (7, 8) . Like the screening assays, each of these 57 only detected IgG anti-HIV and had antibody negative windows of 6 weeks or greater. A testing 58 algorithm was developed where reactive specimens were repeated in duplicate. If one or both of the 59 duplicates were reactive, the confirming procedure was performed. Only specimens that were 60 repeatedly reactive in the screening test and reactive on the confirmatory test had a final interpretation 61 as positive. Positive predictive value of a reactive HIV screening test could be less than 50% in low risk 62 populations (9). Clearly there was a need for better tests that could be used for the diagnosis of HIV 63 In the late 1990s, manufacturers developed HIV assays that combined antibody and antigen detection. 90
As before, these were ELISA and chemiluminescent based procedures. These tests reduced the test 91 negative window to approximately 2 weeks. While both antibody and antigen were detected in these 92 procedures, the test only gave a single result and did not differentiate whether a positive result was due 93 to the presence of the HIV-1 p24 antigen or due to the presence of antibody to HIV-1 or 2. While these 94 tests had been used outside of the United States for many years, the first 4 th generation procedure 95 cleared by the FDA was the Abbot Architect method that was approved in August of 2010. Chavez et al, 96
found the Architect had a sensitivity of 99.94% and a repeat testing specificity of 99.5% in a cohort of 97 3386 HIV infected individuals, 7551 uninfected subjects and 58 patients with acute HIV infection (11). Specimens that are negative on the molecular assay are considered to be false positive screening 119 results. The fourth generation tests and algorithm have improved both sensitivity and specificity in 120 detecting early HIV infection when compared to the previous algorithm using western blots as the 121 confirmatory procedure (12,13, fig 3) . 
